The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 05, 2019

Filed:

Nov. 25, 2016
Applicant:

Abclon Inc., Seoul, KR;

Inventors:

Jong Seo Lee, Gyeonggi-do, KR;

Kyu Tae Kim, Gyeonggi-do, KR;

Bong Kook Ko, Seoul, KR;

Ki Hyun Kim, Seoul, KR;

Hyun Jong Lee, Incheon, KR;

Assignee:

ABCLON INC., Seoul, KR;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/28 (2006.01); G01N 33/577 (2006.01); A61P 37/06 (2006.01); A61P 35/00 (2006.01);
U.S. Cl.
CPC ...
C07K 16/2863 (2013.01); A61P 35/00 (2018.01); A61P 37/06 (2018.01); G01N 33/577 (2013.01);
Abstract

A novel antibody against VEGFR2 for use in the prevention or treatment of macular degeneration and cancer, which are angiogenesis-related diseases. The antibody of the present invention is an antibody which specifically binds to VEGFR2 which is overexpressed in vascular endothelial cells. The antibody of the present invention has very low homology compared to the CDR sequences of conventional VEGFR2 target antibodies, and thus is unique in its sequence. Since the antibody of the present invention, when treated alone, has the ability to inhibit vascular endothelial cell growth equivalent to that of ramucirumab which is conventionally used, it is very effective to prevent or treat angiogenesis-related diseases.


Find Patent Forward Citations

Loading…